Mukul Gupta, MD
Basic profileMukul Gupta is an Oncology physician affiliated with Sansum Medical Clinic. OpenAlex indexes 7 publications with 3,054 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- NovartisProgram year20252 paymentsResearch$356,676
- BioNTech SEProgram year202534 paymentsResearch$93,336
- RegeneronProgram year202513 paymentsResearch$41,900
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
39.2%Iron, parenteral preparations24.3%Ferric carboxymaltose100%Part B, office-administered≥33 patientsErythropoiesis-stimulating Agent14.7%Darbepoetin alfa100%Part B, office-administered≥31 patients+ 1 more class in this area
Cancer & immunology
34.5%PD-1 inhibitor26.9%Nivolumab62%Pembrolizumab38%Part B, office-administered≥19 patientsPlatinum-based Drug6.4%Oxaliplatin97%Carboplatin4%Part B, office-administered≥16 patients+ 12 more classes in this area
Metabolism & gastrointestinal
11.8%Other antiemetics9.7%Fosaprepitant100%Part B, office-administered≥44 patientsSerotonin-3 Receptor Antagonist1.9%Palonosetron hcl53%Granisetron hydrochloride46%Ondansetron Odt1%Ondansetron Hcl0%Part D + Part B<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM).
Journal of Clinical Oncology
2022 - Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. The Phase 2 KEYNOTE-180 Study
UCL Discovery (University College London)
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Andrew Mester, MD
Sansum Medical Clinic
Gregory Cogert, MD
Sansum Medical Clinic
Julie Taguchi, MD
Sansum Medical Clinic
Scott Tobis, MD
Sansum Medical Clinic
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”